ArticleAntimicrobial agents and chemotherapy2009
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 85 citations in OpenAlex.
- Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.Antimicrobial agents and chemotherapy · 2013Trial
- Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.Antimicrobial agents and chemotherapy · 2013Trial
- Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.Antimicrobial agents and chemotherapy · 2011Trial
- The Role of Antimicrobial Susceptibility and Resistance Testing forOpen forum infectious diseases · 2026Article
- Antimicrobial Susceptibility and Distribution Characteristics ofPharmaceuticals (Basel, Switzerland) · 2026Article
- A Case of Refractory Mycoplasma Pneumonia With Extra-pulmonary Manifestations in a Community-Acquired Setting.Cureus · 2025Article
- The Current Landscape of Antibiotic Use and Antimicrobial Resistance in Japan: Focusing on Common Infections Including Uncomplicated Urinary Tract Infection and Gonorrhea.Antibiotics (Basel, Switzerland) · 2025Review
- Article
- Article
- Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia.European journal of pediatrics · 2024Review
- Article
- Hyperammonemia in a septic patient with Ureaplasma parvum arthritis: a case report.BMC infectious diseases · 2022Article
- Construction of a Nomogram for Identifying RefractoryJournal of inflammation research · 2022Article
- Article
- Traditional Chinese Medicine Oral Liquids Combined With Azithromycin forFrontiers in pharmacology · 2021Review
- Recent advances in understanding and combattingFaculty reviews · 2020Review
- Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.Antimicrobial agents and chemotherapy · 2019Article
- Review
- New Horizons in Mycoplasma genitalium Treatment.The Journal of infectious diseases · 2017Review
- Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines.PLoS medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MICs were determined for an investigational ketolide, CEM-101, and azithromycin, telithromycin, doxycycline, levofloxacin, clindamycin, and linezolid against 36 Mycoplasma pneumoniae, 5 Mycoplasma genitalium, 13 Mycoplasma hominis, 15 Mycoplasma fermentans, and 20 Ureaplasma isolates. All isolates, including two macrolide-resistant M. pneumoniae isolates, were inhibited by CEM-101 at < or = 0.5 microg/ml, making CEM-101 the most potent compound tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.